Evidence map›Paper›PMID 19553548›Full record

ArticleClinical and vaccine immunology : CVI2009

Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa.

Gillian F Black, Bonnie A Thiel, Martin O Ota, Shreemanta K Parida, Richard Adegbola, W Henry Boom, Hazel M Dockrell, Kees L M C Franken, Annemiek H Friggen, Philip C Hill and 10 more

Abstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. A Systematic Review on NovelFrontiers in immunology · 2018
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Immunodominant Tuberculosis Antigens Recognized by Human CD4Cold Spring Harbor perspectives in medicine · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Frontiers in cellular and infection microbiology · 2023
    Article
  12. Review
  13. Article
  14. Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022
    Review
  15. Article
  16. Identification andHeliyon · 2020
    Article
  17. Article
  18. Identification of gene fusion events inNAR genomics and bioinformatics · 2020
    Article
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Gillian F BlackDepartment of Biomedical Sciences, Fisan Building, Faculty of Health Sciences, Stellenbosch University, Tygerberg Hospital Campus, Tygerberg, Cape Town, South Africa. gfb@sun.ac.za
Bonnie A Thiel
Martin O Ota
Shreemanta K Parida
Richard Adegbola
W Henry Boom
Hazel M Dockrell
Kees L M C Franken
Annemiek H Friggen
Philip C Hill
Michel R Klein
Maeve K Lalor
Harriet Mayanja
Gary Schoolnik
Kim Stanley
Karin Weldingh
Stefan H E Kaufmann
Gerhard Walzl
Tom H M Ottenhoff
GCGH Biomarkers for TB Consortium

Funding

Medical Research Council MC_U190071468
6 · The paper itself

Abstract

Increasing knowledge about DosR regulon-encoded proteins has led us to produce novel Mycobacterium tuberculosis antigens for immunogenicity testing in human populations in three countries in Africa to which tuberculosis (TB) is endemic. A total of 131 tuberculin skin test-positive and/or ESAT-6/CFP10-positive, human immunodeficiency virus-negative adult household contacts of active pulmonary TB cases from South Africa (n = 56), The Gambia (n = 26), and Uganda (n = 49) were tested for gamma interferon responses to 7 classical and 51 DosR regulon-encoded M. tuberculosis recombinant protein antigens. ESAT-6/CFP10 fusion protein evoked responses in >75% of study participants in all three countries. Of the DosR regulon-encoded antigens tested, Rv1733c was the most commonly recognized by participants from both South Africa and Uganda and the third most commonly recognized antigen in The Gambia. The four most frequently recognized DosR regulon-encoded antigens in Uganda (Rv1733c, Rv0081, Rv1735c, and Rv1737c) included the three most immunogenic antigens in South Africa. In contrast, Rv3131 induced the highest percentage of responders in Gambian contacts (38%), compared to only 3.4% of Ugandan contacts and no South African contacts. Appreciable percentages of TB contacts with a high likelihood of latent M. tuberculosis infection responded to several novel DosR regulon-encoded M. tuberculosis proteins. In addition to significant similarities in antigen recognition profiles between the three African population groups, there were also disparities, which may stem from genetic differences between both pathogen and host populations. Our findings have implications for the selection of potential TB vaccine candidates and for determining biosignatures of latent M. tuberculosis infection, active TB disease, and protective immunity.

Indexed as

AdolescentAdultAgedAntigens, BacterialBacterial ProteinsCells, CulturedChildDNA-Binding ProteinsFemaleGambiaHumansInterferon-gammaLeukocytes, MononuclearMaleMiddle AgedMycobacterium tuberculosisAntigens, BacterialBacterial ProteinsDNA-Binding ProteinsDosR protein, Mycobacterium tuberculosisInterferon-gammaProtein Kinases

Identifiers

PMID19553548
PMCPMC2725533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.